According to Curevac, data from the new phase 1 study are expected in the second half of 2022.
(Photo: imago images/Pacific Press Agency)
tubingen The Tübingen biopharmaceutical company Curevac has signed a contract with the federal government for the production of corona vaccines. The federal government will thus have access to Curevac’s production capacity in order to be able to quickly provide 80 million vaccine doses during the current pandemic or in future outbreaks, as a spokeswoman announced on Monday in Tübingen.
According to the information, the mRNA vaccine is to be produced by Curevac and the pharmaceutical company GlaxoSmithKline (GSK).
Initially, a two-year so-called qualification phase is planned to prepare for production. The federal government will then pay an annual fee for the provision of production capacities until 2029. Curevac did not name a sum on request. The contract is intended to reduce the risk of potential supply bottlenecks in a pandemic situation, it said.
Curevac started a clinical study of its new vaccine candidate against Corona at the end of March. After the first vaccine candidate CVnCoV was withdrawn from the approval process due to comparatively weak efficacy, Curevac and its British partner GSK began developing a new vaccine. The preparation of the Tübingen company is a so-called mRNA vaccine – like the vaccines from Biontech/Pfizer (Germany/USA) and Moderna (USA).
Top jobs of the day
Find the best jobs now and
be notified by email.
According to Curevac, data from the new phase 1 study are expected in the second half of 2022.
More: Curevac falls further behind Biontech and Moderna in vaccine development